



## **Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference**

November 17, 2020

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- [Morphic Therapeutic](#) (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to participate in the Jefferies Virtual London Healthcare Conference with a Company presentation at 2:55 PM ET on Wednesday, November 18, 2020.

A live webcast of the company presentation will be available on the Investor section of Morphic's website at [www.morphictx.com](http://www.morphictx.com). An archived replay will be available on the company's website following the conference.

### **About Morphic Therapeutic**

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit [www.morphictx.com](http://www.morphictx.com).

### **Contacts**

Morphic Therapeutic  
Chris Erdman  
[chris.erdman@morphictx.com](mailto:chris.erdman@morphictx.com)  
617.686.1718